Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06936735 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Oct 28, 2027 to Aug 31, 2028 · Completion date: Nov 27, 2027 to Feb 28, 2029 · Start date changed from estimate of Apr 17, 2025 to May 29, 2025 · 5 morev2 Show 8 more changesShow less
    • Primary completion date: Oct 28, 2027 to Aug 31, 2028
    • Completion date: Nov 27, 2027 to Feb 28, 2029
    • Start date changed from estimate of Apr 17, 2025 to May 29, 2025
    • Secondary endpoints: 8 to 9
    • Study description expanded, about 10 words
    • Study site revised
    • Study arms: 4 to 9
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.
Trial Details
NCT Number NCT06936735
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumor
Enrollment 502 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov